Prognosis Calculator for Relapsed/Refractory DLBCL

Estimate survival in relapsed/refractory DLBCL

Questions

1.Age at First Progression or Relapse
2.Time to progression on frontline immunochemotherapy

About

This prognostic tool was developed to provide prognostic information on survival at the time of first progression or relapse for patients with DLBCL who were treated with frontline R-CHOP or like anthracycline based immunochemotherapy. The risk estimations were developed using data from N=1011 patients who progressed after frontline treatment on randomized clinical trials. Observed 2-year survival was higher than predicted by the model when the risk model was applied to two independent cohorts comprised of patients who were not treated on frontline clinical trials. Therapy selection in the relapsed/refractory setting may impact the risk estimates obtained in the model.

Created by on 21/10/2019

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.

1. Age at First Progression or Relapse

Years
0/2 completed